DETECTION OF B CELL ANTIBODY RESPONSES IN PATIENTS WITH HAEMOPHILIA AND TREATMENT THEREOF
Embodiments of this disclosure include in vitro tests to detect clotting factor-specific antibodies produced by B cells from peripheral blood mononuclear cells (PBMCs) in patients with haemophilia that develop resistance to substitution therapy. Additional embodiments include therapeutic methods for...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French German |
Published |
10.07.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Embodiments of this disclosure include in vitro tests to detect clotting factor-specific antibodies produced by B cells from peripheral blood mononuclear cells (PBMCs) in patients with haemophilia that develop resistance to substitution therapy. Additional embodiments include therapeutic methods for treating patients with haemophilia who have been identified at risk of developing B cell mediated resistance to clotting factor-reconstitution (or substitution) therapy, or have developed resistance to such therapy, by selectively inactivating the B cells that produce clotting factor-specific antibodies, and monitoring the efficiency of the latter treatment by measuring the residual clotting factor-specific B cells in these subjects. |
---|---|
Bibliography: | Application Number: EP20220865244 |